Tonix Q2 net loss $28.3M; cash $125.3M; FDA PDUFA Aug 15 for TNX-102 SL

Tonix Pharmaceuticals Holding Corp.

2025-Q2 EPS reported -$6.80 vs consensus -$3.28 ▼ miss (-107.4%)

Net product revenue $2.0M (down from $2.2M YoY); SG&A surged to $16.2M from $7.5M on pre-launch spend.
Cash $125.3M at June 30; plus $51.5M raised in Q3 2025; runway into Q3 2026.
FDA PDUFA date Aug 15, 2025 for TNX-102 SL (fibromyalgia); Fast Track designation.
First patient dosed in DoD-funded OASIS trial of TNX-102 SL for acute stress reaction.
Appointed Joseph Hand as General Counsel and James Hunter to board; added to Russell 2000/3000.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.